$ORCL

House committee subpoenas Oracle’s Ellison about costly veterans health records project

The House Veterans' Affairs Committee subpoenaed Oracle's Larry Ellison and CEO Mike Sicilia to explain cost overruns in a VA health records project, now estimated at $27B, nearly triple the initial $10B. The project, using Oracle's software, has faced delays and criticism from lawmakers. VA officials remain confident it will stay within the new budget.

Original reporting
Published Sep 2, 2026, 6:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
House committee subpoenas Oracle’s Ellison about costly veterans health records project — source image
Decision brief

The 30-second read

$ORCLBearishLow
01

Why it matters

The subpoena signals heightened congressional oversight and could lead to further investigations or contract adjustments.

02

Market read

The development introduces regulatory risk for Oracle and may affect sentiment toward tech firms with large government contracts.

03

What to watch

Oracle's diversified cloud portfolio may offset any fallout from the VA contract issue.

Relevance 7/10Novelty 7/10Timing: Wednesday (announcement date)

Background

Oracle provides the software platform for the Department of Veterans Affairs' electronic health records overhaul, a project now projected to cost $27 billion.

Company-level read

Ticker impact

$ORCLBearishMedium confidence
Context

Oracle was subpoenaed by the House Veterans' Affairs Committee over the costly VA electronic health records project.

Expected impact

Short-term pressure on ORCL shares, possible dip of 1‑2% pending further developments.

Evidence & confidence

Regulatory inquiries can weigh on investor sentiment, especially for a large‑cap software vendor tied to a high‑profile government contract.

Market effects

Increased scrutiny of enterprise‑software firms involved in government contracts may affect the broader tech services sector.

U.S. markets may see modest downside pressure on defense‑tech and government‑contract stocks.

Limited; the issue is U.S.‑centric and unlikely to move global indices.

Counterpoint

The subpoena could be a one‑off political move with minimal long‑term impact on Oracle's core business.

Key entities

  • Larry Ellison

    Co‑founder of Oracle, subpoenaed to testify.

  • Mike Sicilia

    CEO of Oracle, also subpoenaed.

  • House Veterans' Affairs Committee

    Committee issuing the subpoena.

Related articles

$ORCLMedAI 8/10

$27 Billion and Counting: Budzinski Demands Answers from VA Admin on Exploding Oracle Costs

Congresswoman Nikki Budzinski questioned the VA's plan to give Oracle an additional $17 billion for the EHRM program, bringing the total contract to over $27 billion. Budzinski voted to subpoena Oracle CEO Larry Ellison to address concerns about the growing costs. Oracle reported record revenue of $67.4 billion for fiscal year 2026, up 17 percent, while citing 'unanticipated complexities' for the cost increases.

$ORCLHighAI 9/10

Oracle’s $300B OpenAI Deal Could Be AI’s Weak Link - Oracle (NYSE:ORCL)

Oracle (NYSE:ORCL) faces risks due to its reliance on OpenAI and heavy debt, according to CFR's Sebastian Mallaby. S&P Global cut Oracle's credit rating to BBB-, citing $638B in future revenue tied to OpenAI and $90B-$95B in expected capital expenditure for fiscal 2027. OpenAI has committed to $300B in Oracle computing capacity over five years, raising concerns about its ability to fund these commitments.

$ORCLMedAI 8/10

Can Oracle Get Close to a $1 Trillion Market Cap Again?

Oracle (NYSE: ORCL), down 50% from its peak, has a market cap below $500 billion. Its cloud revenue grew 47% YoY in Q4 2026, with total revenue up 21%. Concerns exist about its $638 billion backlog, heavily tied to OpenAI's $300 billion contract. Oracle's P/E ratio is now 26, with a PEG ratio of 0.86, suggesting undervaluation. The AI market's growth could help Oracle recover.

$ORCLHigh

Citi says investors should consider buying tumbling tech stock

Oracle (ORCL) stock has fallen 23% year-to-date and 56% from its 2025 high. Citi reiterated a Buy rating and $330 price target, citing oversold conditions and strong fundamentals. The bank notes technical pressures like share issuance and credit concerns, but expects AI demand to support Oracle's growth.

$MSFTMedAI 8/10

AI Spending vs Profit in 2026: Microsoft, Alphabet, Amazon, Meta and Oracle Face the ROI Test

Microsoft, Alphabet, Amazon, Meta, and Oracle are investing heavily in AI infrastructure, with investors scrutinizing returns. Microsoft and Alphabet show strong AI-related profit growth, while Amazon's AWS profits contrast with negative free cash flow. Meta's revenue grows, but costs rise faster. A Reuters analysis suggests these companies' capex may exceed combined free cash flow by 2027. Microsoft's Q4 2026 revenue was $90B, with $41B in capex. Alphabet's Q2 2026 revenue was $119.8B, with $24